vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and WW INTERNATIONAL, INC. (WW). Click either name above to swap in a different company.
WW INTERNATIONAL, INC. is the larger business by last-quarter revenue ($184.3M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -30.5%, a 32.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -4.5%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -7.4%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
WW International, Inc., formerly Weight Watchers International, Inc., is a global company headquartered in the U.S. that offers weight loss and maintenance, fitness, and mindset services such as the Weight Watchers comprehensive diet program. Founded in 1963 by Queens, New York City homemaker Jean Nidetch, WW's program has three options as of 2019: online via its mobile app and website, coaching online or by phone, or in-person meetings.
PCRX vs WW — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $184.3M |
| Net Profit | $2.9M | $-56.3M |
| Gross Margin | — | 72.2% |
| Operating Margin | 3.9% | 5.8% |
| Net Margin | 1.6% | -30.5% |
| Revenue YoY | 5.0% | -4.5% |
| Net Profit YoY | — | -21.8% |
| EPS (diluted) | $0.07 | $-5.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | — | ||
| Q3 25 | $179.5M | $184.3M | ||
| Q2 25 | $181.1M | — | ||
| Q1 25 | $168.9M | $186.6M | ||
| Q4 24 | $187.3M | $184.4M | ||
| Q3 24 | $168.6M | $192.9M | ||
| Q2 24 | $178.0M | $202.1M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-56.3M | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $4.8M | $-72.6M | ||
| Q4 24 | — | $25.1M | ||
| Q3 24 | $-143.5M | $-46.2M | ||
| Q2 24 | $18.9M | $23.3M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | 72.2% | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | 71.2% | ||
| Q4 24 | 78.7% | 69.7% | ||
| Q3 24 | 76.9% | 67.1% | ||
| Q2 24 | 75.1% | 67.9% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 3.5% | 5.8% | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | -10.8% | ||
| Q4 24 | 13.2% | 19.6% | ||
| Q3 24 | -82.8% | -20.2% | ||
| Q2 24 | 15.9% | 17.8% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -30.5% | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | 2.8% | -38.9% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | -85.1% | -23.9% | ||
| Q2 24 | 10.6% | 11.5% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | $-5.63 | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | $-0.91 | ||
| Q4 24 | $0.38 | $0.34 | ||
| Q3 24 | $-3.11 | $-0.58 | ||
| Q2 24 | $0.39 | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $170.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $323.0M |
| Total Assets | $1.2B | $968.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | $170.1M | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | $236.3M | ||
| Q4 24 | $484.6M | $53.0M | ||
| Q3 24 | $453.8M | $57.2M | ||
| Q2 24 | $404.2M | $42.7M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $1.4B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | — | ||
| Q3 25 | $727.2M | $323.0M | ||
| Q2 25 | $757.8M | — | ||
| Q1 25 | $798.5M | $-1.2B | ||
| Q4 24 | $778.3M | $-1.1B | ||
| Q3 24 | $749.6M | $-1.1B | ||
| Q2 24 | $879.3M | $-1.1B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $968.8M | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | $696.9M | ||
| Q4 24 | $1.6B | $550.3M | ||
| Q3 24 | $1.5B | $562.4M | ||
| Q2 24 | $1.6B | $614.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $8.4M |
| Free Cash FlowOCF − Capex | — | $8.4M |
| FCF MarginFCF / Revenue | — | 4.6% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $44.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | — | ||
| Q3 25 | $60.8M | $8.4M | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $35.5M | $15.0M | ||
| Q4 24 | $33.1M | $4.6M | ||
| Q3 24 | $53.9M | $16.5M | ||
| Q2 24 | $53.2M | $-1.9M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | $8.4M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | $15.0M | ||
| Q4 24 | $31.0M | $4.5M | ||
| Q3 24 | $49.8M | $16.4M | ||
| Q2 24 | $51.6M | $-2.2M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | 4.6% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | 8.0% | ||
| Q4 24 | 16.6% | 2.4% | ||
| Q3 24 | 29.6% | 8.5% | ||
| Q2 24 | 29.0% | -1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | 0.0% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | 0.0% | ||
| Q4 24 | 1.1% | 0.1% | ||
| Q3 24 | 2.4% | 0.1% | ||
| Q2 24 | 0.9% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | -0.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
WW
Segment breakdown not available.
